Analyst Price Target is $105.25
▲ +6.06% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Celcuity in the last 3 months. The average price target is $105.25, with a high forecast of $134.00 and a low forecast of $60.00. The average price target represents a 6.06% upside from the last price of $99.24.
Current Consensus is
Moderate Buy
The current consensus among 10 investment analysts is to moderate buy stock in Celcuity. This rating has held steady since September 2025, when it changed from a Buy consensus rating.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Read More
